 NEW YORK and LONDON, July 01, 2020 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Akari or the Company AKTX, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and or leukotriene systems are implicated, today announces that it has entered into a Securities Purchase Agreement the Agreement of up to 30 million with Aspire Capital Fund, LLC Aspire Capital. Under the terms of the Agreement, Aspire Capital has committed to purchase up to 30 million of Akaris American Depositary Shares ADSs at Akaris request from time to time during a period beginning on the effective date of a registration statement related to the transaction, and at prices based on the market price at the time of each sale. 